Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06365190
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-02
Brief Title:
Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease
Sponsor:
Anhui Medical University
Organization:
Anhui Medical University
Study Overview
Official Title:
Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Previous studies have shown that repetitive transcranial magnetic stimulationrTMS can improve clinical symptoms of Parkinsons diseasePD Continuous theta-burst stimulationcTBS is a novel rTMS protocol that produces physiological effects b acting on neurons in the brain which can decrease the excitability of motor system This study aims to explore the long-term effects of cTBS on improvement of movement symptoms in patients with PD
Detailed Description:
This was a open-label clinical trial to assess the Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease
Participants were randomly assigned to the cTBS group and the control group on a 11 basis using age as a stratification factor In the cTBS group after baseline assessment participants received cTBS treatment on the left supplementary motor areaSMA for 14 days and symptoms were assessed on the second day after treatment Ten weeks after completion of assessment a second cTBS session was performed with all patients taking stable doses of antiparkinsonian medications The control group only received drug intervention and symptom assessment was conducted at weeks 13 23 33 and 43 To rule out the influence of medication on symptom assessment all patients stopped taking medication for at least 12 hours before assessment
Participants were randomly assigned to the cTBS group and the control group on a 11 basis using age as a stratification factor In the cTBS group after baseline assessment participants received cTBS treatment on the left supplementary motor areaSMA for 14 days and symptoms were assessed on the second day after treatment Ten weeks after completion of assessment a second cTBS session was performed with all patients taking stable doses of antiparkinsonian medications The control group only received drug intervention and symptom assessment was conducted at weeks 13 23 33 and 43 To rule out the influence of medication on symptom assessment all patients stopped taking medication for at least 12 hours before assessment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None